Spyre Therapeutics SYRE
$93.47 −$4.16 (-4.26%)
Market closed · Nov 22, 5:50 am ET · Last extended-hours $93.47 0.00%
Open$95.93
Prev close$97.63
Day range$93.22 – $99.56
Volume805.4K
Market cap$8.88B
P/E (TTM)–
Dividend yield–
SYRE Stock News
Headlines matching Spyre Therapeutics or the SYRE ticker, most recent first.
- Jefferies Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $126 Positive
- Leerink Partners Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128 Positive
- LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $116
- Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123
- JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $121
- LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128 Positive
- Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $130 Positive
- A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $116 to $130
- Guggenheim Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $130
- A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $115 to $127
- LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $129
- Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123
- JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $140 Positive
- BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $132 Positive
- LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $129 Positive
No comments yet — be the first to weigh in on SYRE.
Sign in to join the discussion.